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116 intervals (CIs) were used in some studies; we calculated the SD using the formula: ((upper 117 limit of 95% CI - lower limit of 95% CI)/(2 × 1.96)) × √(n). Publication bias is defined as a 118 condition in which studies with positive results are more likely to be published. Assessment 119 of the risk of bias was performed following the Cochrane handbook.
121 Risk of bias assessment
122 Two authors (ZZ and YY) independently assessed risk of bias using the Cochrane 123 risk-of-bias tool (8) . They reviewed each trial and gave a score of high, low, or unclear risk of 124 bias according to the following criteria: random sequence generation, allocation concealment, 125 blinding of participants and personnel to the study protocol, blinding of outcome assessment, 126 incomplete outcome data, selective reporting, and other bias. 133 For continuous outcomes, the differences in means and the 95% CI in mean change between 134 baseline and end of treatment value were calculated for individual trials, and the weighted 135 mean difference (WMD) was used as a summary estimator. Dichotomous outcome data from 136 individual trials were analyzed using the relative risk (RR) measure and 95% CI.
137 Heterogeneity of treatment effects between studies was investigated visually by examination 7 139 was taken to indicate statistical significance. The fixed-effects and random-effects models 140 were used for the meta-analysis of each indicator. Analyses were performed using Review 141 Manager 5.2 (RevMan; Cochrane Collaboration, Oxford, UK).
142
143 Trial sequential analyses 144 To evaluate whether the present meta-analysis had a sufficient sample size to reach firm 145 conclusions about the effects of interventions, we performed trial sequential analyses (TSAs) 146 for outcomes, which involves a cumulative meta-analysis to create a Z curve of the 147 summarized observed effect (the cumulative number of included patients and events) and the 148 monitoring boundaries for benefit and harm and estimate the optimal sample size (9). When 149 the cumulative z curve crosses the trial sequential monitoring boundary, a sufficient level of 150 evidence for the anticipated intervention effect may have been reached. If the z curve crosses 151 none of the boundaries and the required information size has not been reached, there is 152 insufficient evidence to reach a conclusion. These analyses were performed using the 153 software TSA version 0.9 Beta (Copenhagen Trial Unit, Copenhagen, Denmark). 240 Fig. 6 ). These analyses were dominated by the steroid treatment group (Fig. 7) .
241 TSAs of steroids indicated that the cumulative z curve crossed both the conventional 242 boundary and the trial sequential monitoring boundary. 246 CI, confidence interval; RR, relative risk.
247
248 Adverse events of treatment 10 250 adverse events varied widely, and included infection, cardiovascular disease, respiratory 251 disease, hepatotoxicity, and many others; the 12 most commonly reported are listed in Table   252 2. As the number of infections reported in Rauen (30) 
